
    
      Specific aims of this study are:

        1. To evaluate efficacy of Pirfenidone in NF1 patients with disfiguring or disabling
           plexiform neurofibroma (PN) and spinal neurofibromas (SN)

        2. To determine the acute, subacute and chronic toxicity of Pirfenidone in patients with
           NF1.
    
  